Tegillarca granosa extract Haishengsu inhibits the expression of p-glycoprotein and induces apoptosis in drug-resistant K562/ADM cells

Pharmaceutical Biology

Volumn 48, Issue 5, 2010, Pages 529-533

  Li, Guang Yao ^a   Liu, Ji Zhu ^a   Chen, Shou Guo ^b   Zhang, Bin ^a   Wang, Chun Bo ^c   Wang, Le Xin ^d  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b Haisheng Oncology Hospital of Qingdao   (China)

^c QINGDAO UNIVERSITY   (China)

^d CHARLES STURT UNIVERSITY   (Australia)

Author keywords

Apoptosis; Haishengsu; K562 ADM; Leukemia; P glycoprotein

Indexed keywords

CASPASE 3; DOXORUBICIN; GLYCOPROTEIN P; HAISHENGSU; PROTEIN BCL 2; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL STRAIN K 562; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FLOW CYTOMETRY; LEUKEMIA CELL LINE; MOLECULAR MECHANICS; NONHUMAN; PROTEIN EXPRESSION; RAT; SHELLFISH; TEGILLARCA GRANOSA;

ALBUMINS; ANIMALS; APOPTOSIS; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; GENE EXPRESSION REGULATION; HUMANS; K562 CELLS; P-GLYCOPROTEIN; PILOT PROJECTS; SHELLFISH;

TEGILLARCA; TEGILLARCA GRANOSA;

EID: 77951872372     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880200903176620     Document Type: Article

References (16)

1. Boatright KM, Salvesen GS (2003): Mechanisms of caspase activation. Curr Opin Cell Biol 15:725-731.
2. Cohen GM (1997): Caspases: The executioners of apoptosis. Biochem J 326:1-16.
3. Ford JP, Hoggard G, Owen A, Khoo SH, Back DJ (2003): A simplified approach to determining p-glycoprotein expression in peripheral blood mononuclear cell subsets. J Immunol Methods 274:129-137.
4. Gupta S, Afaq F, Mukhtar H (2002): Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 21:3727-3738.
5. Higgins CF (1992): ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8:67-113.
6. Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vanky F (1976): Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 18:421-431.
7. Jung WK, Jo HY, Qian ZJ, Jeong YJ, Park SG, Choi IW, Kim SK (2007): A novel anticoagulant protein with high affinity to blood coagulation factor Va from Tegillarca granosa. J Biochem Molecular Biol 40:832-838.
8. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J (2006): New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Anna Intern Med 145:913-923.
9. Li GY, Liu JZ, Yu XM, Chen SF, Zhang B, Zhang WF, Wang LX (2008): Effect of a seashell protein haishengsu on cell growth and expression of apoptosis genes in leukemia K562 Cells. Clin Invest Med 31: E218-E221.
10. Li GY, Yu XM, Zhang HW, Zhang B, Wang CB, Xin YC, Yang CZ, Zhou RX, Wang LX (2008): Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: A pilot randomized and placebo-controlled clinical trial. Complement Ther Med 2009;17:51-55.
11. Liu ZX, Zhan SM, Yao RY, Fang LH, Yang X, Wang CB (2004): An experimental study on anti-tumor effect of Haishengsu injection. Chin J Mar. Drugs 23:35-37.
12. Tsuruo T, Iida-Saito H, Kawabata H, Oh-hara T, Hamada H, Utakoji T (1986): Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones. Jpn J Cancer Res 77:682-692.
13. Wang ZL, Chu X, Yang X, Chen SQ, Wang CB (2006): Antitumor effects of extractive from Arca granosa Linnaeus. Shandong Med J 46:69-73.
14. Yang CZ, Luan FJ, Xiong DS, Liu BR, Xu YF, Gu KS (1995): Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin. Acta Pharmacol Sin 16:333-337.
15. Yao RY, Chu X, Zhang YJ, Yang X, Liu XR, Wang CB (2005): Anti-tumor effect of Haishengsu extracted from Tegillarca granosa in vitro and in vivo. Chin J Mar. Drugs 24:33-36.
16. Zhang CX, Li GY, Han CS, Ye XQ, Chen HY, Zhou HJ, Chen SG (2005): Effect of Haishengsu preparation extracted from Tegillarca granosa in treatment of intermediate and late non-small-cell lung cancer (NSCLC) and late renal cancer. Chin J Mar. Drugs 24:55-58.